Video Experimental Relacionado

Updated: May 2, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Eventos trombóticos cardiovasculares en ensayos clínicos controlados de rofecoxib en pacientes con trastornos

M A Konstam¹, M R Weir, A Reicin

¹Division of Cardiology, New England Medical Center, Boston, Massachusetts, USA. MKonstam@Lifespan.org

|November 7, 2001

Resumen

Rofecoxib no mostró un aumento en los eventos trombóticos cardiovasculares en comparación con el placebo o los AINE sin naproxeno. El naproxeno es el naproxeno.

Área de la Ciencia:

Medicina cardiovascular La medicina cardiovascular es una especialidad de la medicina cardiovascular.
Farmacología Farmacología.
Medicina interna La medicina interna es el tratamiento de enfermedades.

Sus antecedentes:

Los antiinflamatorios no esteroideos (AINE) y los inhibidores de la ciclooxigenasa (COX)-2 varían en sus efectos inhibidores de las plaquetas.
Esta variación puede influir en los riesgos de eventos trombóticos cardiovasculares (CV).
Estudios anteriores sugirieron diferencias en el riesgo CV entre rofecoxib y naproxeno.

Objetivo del estudio:

Para determinar si el uso de rofecoxib está asociado con un exceso de eventos trombóticos CV.
Para comparar el riesgo de evento trombótico CV de rofecoxib con placebo y AINE no selectivos.
Para analizar los datos de pacientes individuales de ensayos controlados aleatorios.

Principales métodos:

Análisis combinado de los datos de pacientes individuales de 23 estudios con rofecoxib (Fase IIb-V).
Comparó el rofecoxib con el placebo, el naproxeno y otros AINE no selectivos (diclofenac, ibuprofeno, nabumetona).
Eventos trombóticos cardiovasculares mayores evaluados utilizando el criterio de valoración de la Colaboración de Trialistas Antiplaquetarios.

Principales resultados:

Se analizaron más de 28.000 pacientes y 14.000 pacientes-años.
Rofecoxib no mostró un exceso de eventos cardiovasculares en comparación con el placebo (RR 0.84) o los AINE sin naproxeno (RR 0.79).
Rofecoxib mostró un mayor riesgo de eventos cardiovasculares en comparación con el naproxeno (RR 1.69).

Conclusiones:

No hay evidencia de exceso de eventos cardiovasculares con rofecoxib en comparación con el placebo o los AINE sin naproxeno.
Las diferencias observadas entre rofecoxib y naproxeno probablemente se deben a los efectos antiplaquetarios de naproxeno.
La actividad antiplaquetaria del naproxeno puede conferir un beneficio protector cardiovascular.

Más Videos Relacionados

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Videos de Conceptos Relacionados

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...